II Asco em Contexto

DATA: 19 de junho

Apresentação: O Congresso Anual da Sociedade Americana de Oncologia Clínica (ASCO) traz inúmeras novidades com impacto direto na prática da oncologia. O objetivo desse evento é discutir os principais resultados apresentados em cada área, e trazê-los para o dia a dia do cuidado oncológico.

Público-alvo: Oncologistas clínicos, cirurgiões, rádio-oncologistas e médicos residentes.


Acessar a Live


Programação: 19 de junho de 2021 (sábado)
*Programação sujeita a alterações e confirmações de convidados

08h00 – 08h10

Palestrante: Dr. Artur Katz

Coordenador: Dr. Artur Katz.

08h10 - 08h40

Trabalhos selecionados – Parte 1 – Doença Inicial
Palestrante: Dra. Marina Sahade

  • Abstract 506: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
  • Abstract 605: A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131
  • Abstract 505: Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutatio-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
  • LBA1: OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
  • Abstract 509: Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF<50%).

08h40 - 09h10

Trabalhos selecionados – Parte 2 – Doença avançada
Palestrante: Dra. Andrea Shimada

  • Abstract 1002: Dalpiciclib versus placebo plus fulvestrant in HR+/HER2-advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
  • Abstract 1000: Overall survival (OS) with palbociclib (PAL) + fuvestrant (FUL) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
  • Abstract 1001: Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
  • Abstract 1007: Combination of famitinib with camrelizumab plus nab-paclitaxel as firs-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.
  • Abstract 1020: Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.
  • Abstract 1024: Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.

09h10 - 09h25

Resultados em perspectiva
Palestrante: Dr. Carlos dos Anjos

09h25 - 09h35

Discussão e Q&A
Moderador: Dr. Romualdo Barroso
Debatedores: Dra. Marina Sahade, Dra. Andrea Shimada e Dr. Carlos dos Anjos

Coordenador: Dr. Olavo Feher

09h35 - 10h05

Trabalhos selecionados
Palestrante: Dr. Rodrigo Medeiros

  • Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas
  • Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors
  • Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG)
  • Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles.

10h05 - 10h20

Resultados em perspectiva
Palestrante: Dr. Olavo Feher

10h20 - 10h30

Discussão e Q&A
Moderador: Dr. Olavo Feher
Debatedor: Dr. Rodrigo Medeiros

10h30 - 10h40


Coordenador: Dr. Diogo Bastos

10h40 - 11h10

Trabalhos selecionados – Parte 1
Palestrante: Dr. Daniel Girardi

  • Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
  • A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
  • Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort.

11h10 - 11h40

Trabalhos selecionados – Parte 2
Palestrante: Dra. Aline Bobato Lara

  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blinded, phase III Keynote-564 study.
  • embrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426
  • Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.

11h40 - 11h55

Resultados em perspectiva
Palestrante: Dr. Igor Morbeck

11h55 - 12h05

Discussão e Q&A
Moderador: Dr. Denis Jardim
Debatedores: Dr. Daniel Girardi, Dra. Aline Bobato Lara e Dr. Igor Morbeck

12h05 - 13h00


Coordenador: Dr. Jorge Sabbaga

13h00 - 13h30

Trabalhos selecionados – Parte 1 - TGI – colorretal
Palestrante: Dra. Fernanda Capareli

  • Abstract 3504: Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.
  • Abstract 3505: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
  • Abstract 3500: Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

13h30 - 14h00

Trabalhos selecionados – Parte 2 - TGI – não colorretal
Palestrante: Dr. Tulio Pfiffer

  • Abstract 4000: ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
  • Abstract 4001: Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
  • Abstract 4002: First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
  • Abstract 4003: Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.
  • Abstract 4004: Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
  • Abstract 4005: Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

14h00 - 14h15

Resultados em perspectiva
Palestrante: Dr. Gustavo Fernandes

14h15 - 14h25

Discussão e Q&A
Moderador: Dr. Frederico Costa
Debatedores: Dra. Fernanda Capareli, Dr. Tulio Pfiffer e Dr. Gustavo Fernandes

Coordenador: Dr. Gilberto Castro

14h25 - 14h55

Trabalhos selecionados – Parte 1
Palestrante: Dr. Guilherme Harada

  • LBA2 - JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
  • 6000 - Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.
  • 6001 - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.
  • 6003 - Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
  • 6005 - Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.
  • 6008 - Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

14h55 - 15h25

Trabalhos selecionados – Parte 2
Palestrante: Dr. João Victor Alessi

  • 8500 - IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
  • 8505 - Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
  • 8504 - Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET).
  • 8503 - Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
  • 8501 - Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.
  • 9006 - Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
  • 9007 - Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
  • 9003 - Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

15h25 - 15h40

Resultados em perspectiva
Palestrante: Dr. Marcelo Cruz

15h40 - 15h50

Discussão e Q&A
Moderador: Dr. Rodrigo Medeiros
Debatedores: Dr. Guilherme Harada, Dr. João Victor Alessi e Dr. Marcelo Cruz

15h50 - 16h00


Coordenador: Dr. Rodrigo Munhoz

16h00 - 16h20

Trabalhos selecionados – Parte 1
Palestrante: Dr. Allan Andresson

  • 9502: Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
  • 11502: Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.
  • 11504: SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

16h20 - 16h40

Trabalhos selecionados – Parte 2
Palestrante: Dra. Marina Sahade

  • 9503: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
  • 9505: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.
  • 9501: Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

16h40 - 16h55

Resultados em perspectiva
Palestrante: Dr. Rodrigo Munhoz

16h55 - 17h05

Discussão e Q&A
Moderador: Dr. David Muniz
Debatedores: Dr. Allan Andresson, Dra. Marina Sahade e Dr. Rodrigo Munhoz

Coordenadora: Dra. Daniela de Freitas

17h05 - 17h25

Trabalhos selecionados – Parte 1 – Câncer Uterino
Palestrante: Dr. Carlos dos Anjos

  • Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial.
  • Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study).
  • Pertuzumab plus trastuzumab in patients with uterine cancer with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
  • Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.

17h25 - 17h45

Trabalhos selecionados – Parte 2
Palestrante: Dr. Rudinei Linck

  • Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy with or without pembrolizumab followed by interval debulking surgery and standard systemic therapy ± pembrolizumab for advanced high-grade serous carcinoma (HGSC): A GINECO study.
  • Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer.
  • Optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer: A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).
  • Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.

17h45 - 18h00

Resultados em perspectiva
Palestrante: Dra. Daniela de Freitas

18h00 - 18h10

Discussão e Q&A
Moderadora: Dra. Daniela de Freitas
Debatedores: Dr. Carlos dos Anjos, Dr. Rudinei Linck e Dra. Daniela de Freitas

18h10 - 18h15


Inscreva-se em Nossos Cursos

Inscrição em Cursos